InvestorsObserver
×
News Home

What is the Market's View on MEI Pharma Inc (MEIP) Stock's Price and Volume Trends Thursday?

Thursday, November 16, 2023 10:28 AM | InvestorsObserver Analysts

Mentioned in this article

What is the Market's View on MEI Pharma Inc (MEIP) Stock's Price and Volume Trends Thursday?

MEI Pharma Inc (MEIP) stock is lower by 15.01% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
MEI Pharma Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on MEIP!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With MEIP Stock Today?

MEI Pharma Inc (MEIP) stock is down -1.48% while the S&P 500 is higher by 0.07% as of 10:21 AM on Thursday, Nov 16. MEIP is down -$0.09 from the previous closing price of $6.09 on volume of 98,369 shares. Over the past year the S&P 500 is up 12.88% while MEIP is down -12.92%. MEIP earned $6.18 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 0.97. To screen for more stocks like MEI Pharma Inc click here.

More About MEI Pharma Inc

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States. Click Here to get the full Stock Report for MEI Pharma Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App